Influences and safety of ezetimibe combining simvastatin on control rate of LDL-C level in patients with coronary heart disease and diabetes

Objective To observe the influences and safety of ezetimibe combining simvastatin on control rate of level of low-density lipoprotein-cholesterol(LDL-C) in patients with coronary heart disease(CHD) and diabetes.Methods The patients with CHD and diabetes(n=46) whose LDL-C level was not controled well were selected and randomly divided into group of ezetimibe(10 mg/d) combining simvastatin(20 mg/d)(combining group,n=24) and group of simvastatinin in double dose(40 mg/d,simvastatinin group,n=22).The changes of blood fat level after treatment,control rate of LDL-C level on the 4th week,8th week and 12th week,and adverse reactions were observed in two groups.Results On the 4th week,8th week and 12th week after treatment,the control rate of LDL-C level was higher in combining group than that in simvastatinin group,and on the 8th week and 12th week the difference in the control rate showed a statistical significance between two groups(P0.01).On the 12th week,blood fat level was ameliorated in two groups,and the difference in the levels of LDL-C and total cholesterol(TC) had statistical significance compared with those in the same group before the treatment(P0.01 to P0.05).The comparison in the levels of LDL-C and TC showed a significant and statistical difference between two group 12 weeks after treatment(P0.01).The patients could tolerate the treatment in combining group,and in simvastatinin group the drug was increased in dose or ceased in 2 patients(9.1%) because of adverse reactions.Conclusion Ezetimibe combining simvastatin can promote better the control rate of LDL-C level than only simvastatin and can be tolerated well.